GoodRx Expands Offerings with Ozempic Pill, Available for as Low as $149/Month
GDRX sits 35% above its 52-week low of $1.77.
Summary
GoodRx Holdings has expanded its prescription offerings to include the Ozempic® pill for Type 2 Diabetes patients, with pricing starting as low as $149 per month for the 1.5mg dosage, $199 for 4mg, and $299 for 9mg. This is new information and not reflected in recent SEC filings. This development is a material positive for GoodRx, as adding a high-demand and often expensive drug like Ozempic to its platform with competitive pricing could significantly boost user acquisition and engagement. Given the company's reported declining core user metrics and prescription revenue in its last 10-K, this strategic expansion directly addresses a key challenge and could help drive future growth. Investors will be keen to observe the impact of this offering on user numbers and revenue in upcoming financial reports.
At the time of this announcement, GDRX was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $808.5M. The 52-week trading range was $1.77 to $5.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.